Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships

This community-based initiative is designed to leverage the insights and experience of local and national HCV, HIV, and policy experts in the setting of small-group, peer-to-peer education. The purpose of this series of live, regional, multidisciplinary educational interventions is to build connections across local and regional care networks to optimize the identification and treatment of patients with HCV, specifically in the context of HIV/HCV coinfection.

initiative goals

Discuss how the existing HIV-treatment infrastructures can facilitate treatment of HCV among co-infected patients
Identify barriers to HCV elimination relative to local/regional circumstances
Share success stories and best-practices from established care models in other geographic and therapeutic areas
Build linkage-to-care networks within local/regional systems
Begin the establishment of a roadmap specific to regional needs and resources for HCV elimination in HIV/HCV co-infected patients

Program Description

Approximately 25% of all individuals infected with HIV are coinfected with HCV.1 Of critical significance, HIV increases the rate of progression of HCV-related hepatic fibrosis, and HCV is associated with a 3-fold increase in HIV antiretroviral therapy (ART)–induced liver toxicity.2 Further, these synergistic diseases often occur within adverse socioeconomic conditions that significantly increase the vulnerability and decrease the overall health status of at-risk populations.3 Whereas HIV infection is now effectively manageable, chronic HCV infection is curable. Yet, despite new, highly effective direct-acting antiviral (DAA) treatment regimens for HCV, their broad-scale use and associated therapeutic successes remain stymied by barriers at the patient, clinician, health care system, and jurisdictional levels.4 The BLOCK HIV/HCV initiative will provide community-based infectious disease specialists and other HIV treaters with foundational information and practical resources needed to prepare local stakeholders—both clinical and nonclinical—to collaborate in efforts to eliminate HCV within their communities.

  1. Centers for Disease Control and Prevention. HIV/AIDS and Viral Hepatitis. https://www.cdc.gov/hepatitis/populations/hiv.htm.
    Accessed January 24, 2018.
  2. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat. 2007;14(6):371-386.
  3. Singer M. Introduction to Syndemics: A Critical Systems Approach to Public and Community Health. San Francisco, CA: Jossey-Bass; 2009.
  4. National Viral Hepatitis Roundtable (NVHR). Hepatitis C: The State of Medicaid Access. October 23, 2017. https://stateofhepc.org/wp-content/uploads/2017/10/State-of-HepC_2017_FINAL.pdf. Accessed January 24, 2018.

educational objectives

After completing this activity, the participant should be better able to:

Describe epidemiologic trends in HCV monoinfection and HIV/HCV coinfection within at-risk populations, including men who have sex with men (MSM), people who inject drugs (PWID), and incarcerated individuals
Provide guideline-based treatment for HCV monoinfection and HIV/HCV coinfection
Identify patient, provider, and health care system barriers to effective management of HCV monoinfection and HIV/HCV coinfection
Implement strategies to overcome risk-cohort–specific challenges to the treatment of HCV
monoinfection and HIV/HCV coinfection

steering committee

David L. Wyles MD (Course Chair) 
Chief, Division of Infectious Diseases
Denver Health
Professor of Medicine
University of Colorado School of Medicine
Denver, Colorado

Andrew Aronsohn, MD (Chicago Co-Chair) 
Associate Professor of Medicine
Faculty, MacLean Center for Clinical Medical Ethics
Program Director, Transplant Hepatology Fellowship
Co-Principal Investigator, HepCCATT
University of Chicago Medicine
Chicago, Illinois

Ricardo Franco, MD (Birmingham Co-Chair)
Assistant Professor of Medicine
Department of Infectious Diseases
University of Alabama
Birmingham, Alabama

Andrew J. Muir, MD (Asheville Co-Chair)
Professor of Medicine
Chief, Division of Gastroenterology
Department of Medicine
Duke University School of Medicine
Durham, North Carolina

Jennifer Price, MD (Oakland Co-Chair)
Assistant Clinical Professor of Medicine
Hepatology and Liver Transplantation
Department of Medicine
University of California San Francisco
San Francisco, California

Nancy Reau, MD, FAASLD, AGAF (Chicago Co-Chair)
Chief, Section of Hepatology
Richard B. Capps Chair of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois

Takako S. Schaninger, MD (Richmond Co-Chair)
Associate Professor of Medicine
University of Kentucky College of Medicine
Hospital Epidemiologist, VAMC
Bluegrass Care Clinic
Lexington, Kentucky

Stacey Trooskin, MD, PhD, MPH
Director, Viral Hepatitis Programs
Jonathan Lax Treatment Center
Philadelphia FIGHT
Philadelphia, Pennsylvania

Meetings

Chicago, IL

Monday, June 24, 2019

8:00 AM – 3:45 PM

Educational Program

Kimpton Hotel Palomar Chicago
505 N. State Street
Chicago, IL  60654

Oakland, CA

Friday, September 13, 2019

Hilton Garden Inn - Oakland Bay Bridge
1800 Powell Street
Emeryville, CA 94608

Asheville, NC

Monday, September 23, 2019

Renaissance Asheville Hotel
31 Woodfin Street
Asheville, NC  28801

REGISTER NOW

Birmingham, AL

Friday, October 18, 2019

Hyatt Regency Birmingham - The Wynfrey Hotel
1000 Galleria Circle
Birmingham, AL 35244

REGISTER NOW

Richmond, KY

Friday, November 15, 2019

Madison County Extension Office
230 Duncannon Lane
Richmond, KY 40475

REGISTER NOW

Program Agenda

10 minutes

Welcome and Preactivity Polling

30 minutes

The Challenge of HCV Elimination

30 minutes

HCV Therapy: The State of the Union

20 minutes

Populations in Greatest Need—Men Who Have Sex With Men (MSM)

20 minutes

BREAK

30 minutes

Populations in Greatest Need—People Who Inject Drugs (PWID)

20 minutes

Other Real-World Circumstances

20 minutes

Success Stories

30 minutes

LUNCH

30 minutes

Addressing Region-Specific Barriers and Challenges to HCV Elimination

10 minutes

Introduction to Small-Group Breakouts:
Bringing Together Stakeholders and Creating a Collaborative Plan

30 minutes

Multidisciplinary Small Groups: Putting a Plan Into Action

60 minutes

Panel Discussion: The Call to Action & Beyond

20 minutes

Closing Statements & Postactivity Polling

CME InFORMATION

target audience

This activity is intended for a multidisciplinary audience including community-based infectious disease specialists and other HIV treaters, gastroenterology/hepatology clinicians, mental health specialists, substance abuse specialists, correctional health care professionals, public policy/public health officials, hepatitis C virus (HCV) and HIV advocacy groups, payers, and clinical office staff who are engaged in the care of patients with HIV and/or HCV.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the
American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 6.5 contact hours (0.65 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-19-748-L02-P)

Type of activity

Application 

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.  Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 6.5 contact hours.
Pharmacotherapy contact hours for Advanced Practice Registered Nurses to be determined. 

Social Worker and Case Manager credit will be applied for, but is not guaranteed at this time.

Social Worker Education

As a Jointly Accredited Organization, Postgraduate Institute for Medicine is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program.  Organizations, not individual courses, are approved under this program.  State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit.  Postgraduate Institute for Medicine maintains responsibility for this course.  Social workers completing this course receive 6.5 clinical continuing education credits.

Case Manager Education

This program has been submitted to The Commission for Case Manager Certification for approval to provide board certified case managers with 6.5 clock hours.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as
related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. 
The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Nora Eldasher prior to the live event at neldasher@integritasgrp.com.

Fee Information

There is no fee for this educational activity.

2019 Collaborators

In collaboration with:

2018 Collaborators

RESOURCES

For additional clinician and patient resources visit: